Document:

Exhibit 10.62

 

MATERIALS TRANSFER AGREEMENT

 

BC
Cancer Agency

 

This
Agreement is among Advanced Cell Technology, Inc. (“ACT”), B.C. Cancer Research Centre (“The Institution”) and Dr. Peter Lansdorp (“Researcher”).  The Institution and the Researcher are collectively
referred to in this Agreement as the “Recipients.”

 

The
parties hereby agree as follows:

 

1.             Requested Materials. The term “Materials” shall mean the
following tangible materials that are requested by Researcher and furnished by
ACT under the terms of this Agreement:

 

1)     Blood samples from cloned and control cattle.

2)     Embryonic cell samples produced at Advanced Cell Technology.

3)     Fixed and living cells provided.

 

“Materials”
shall also include any other materials routinely produced through use of such
tangible materials, including, for example, any progeny derived from a cell
line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated
from isolated DNA or RNA, recombinant proteins produced by a recombinant cell
line, recombinant proteins produced through use of isolated DNA or RNA, and
substances routinely purified from any source material included in the
materials (such as recombinant proteins isolated from a cell extract or supernatant
by non-proprietary affinity purification methods).

 

2.               Limited Use of Materials. The Recipients agree to use the Materials
only for the following experimental research under the direct supervision of
Researcher, and not for any other purpose:

 

Measurement of telomeres
and telomerase activity

 

The
Recipients shall use the Materials only in compliance with all applicable
federal, state and local laws and regulations. The Recipients shall not use the
Materials in any in vivo experiments on human subjects without the prior
written consent of ACT

 

One
Innovation Drive, Worcester, MA 01605 Tel 508.756.1212 Fax 508.756.0931

 

 

3.               Limited Disposition of Materials.   The
Materials shall remain on the premises of the Institution.   The Recipient shall not distribute any
Materials to any third party other than employees or students of Institution
who are working under the supervision of Researcher. Upon completion of the
research, or sooner at the request of ACT, the Recipient shall at the instruction
of ACT either destroy or return any unused Materials.

 

4.               Ownership of Materials.    The
Recipient acknowledges and agrees that all title and intellectual property
rights in the Materials are and shall be owned by ACT. The Recipient agrees to
execute and deliver and documents of assignment or conveyance to effectuate the
ownership rights of ACT in the Materials.

 

5.               Ownership of Intellectual
Property. The Researcher shall promptly inform ACT
they intend to commercialize, to file a patent application claiming, or to
assert any intellectual property rights in any research results obtained using
the Materials.  ACT agrees to negotiate in
good faith their respective ownership of the research results and any
intellectual property rights therein based on their relative contributions to
such rights and on any applicable laws relating to ownership of such rights,
including without  limitation those
relating to inventorship and authorship.

 

6.               License Option to ACT.   Recipients
shall notify ACT promptly of any discoveries, inventions, data, modifications,
new substances, and other results of any research using the Materials (“Research
Results”).    To the extent permitted by
law and any conflicting obligations to non-profit sponsors of research, the
Recipient hereby grants ACT a first option to obtain an exclusive, worldwide
license under any intellectual property rights in any Research Results (the “License
Option”).    ACT may exercise the License
Option upon written notice and the Recipient within thirty (30) days from the
date upon which ACT receives notice of the relevant Research Results. In the
event that ACT elects to exercise the License Option, the parties shall attempt
to negotiate in good faith to license agreement containing commercially
reasonable terms and pricing.   If the
parties are unable to reach agreement within ninety (90) days after the date
upon which ACT exercised the license option (the “Negotiation Period”).   Then the Recipient will be free to offer
such rights to third parties; provided, however, that for a period of one (1)
year after the Negotiation Period 

 

 

the
Recipient may only offer such rights to third parties on terms and pricing
which in the aggregate are no more favorable than those last offered to ACT,
unless the more favorable terms and pricing have first been offered in writing
to ACT and either (i) ACT has declined in writing to accept such terms and
pricing or (ii) ACT has not responded after a period of thirty (30) days from
the date of such offer. The Recipient shall not use the Materials in research
that is subject to a licensing obligation to another commercial entity without
the prior written consent of ACT.

 

7.              Publication Rights. Researcher shall have the unrestricted right
to publish the results of any research using the Materials; however, in order
to prevent the inadvertent loss of patent rights, the Recipients shall provide
ACT with pre-prints or abstracts of any proposed presentation or paper
describing any Research Results at least sixty (60) days prior to publication.

 

8.              No Warranties.  Any
Materials delivered pursuant to this Agreement are understood to be experimental
in nature and may have hazardous properties. 
ACT MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED.  WITH RESPECT TO THE MATERIALS, AND SPECIFICALLY
DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE  ANY PATENT OR OTHER PROPRIETARY RIGHTS OF A
THIRD PARTY.

 

9.              Indemnification. The Recipient assumes all liability for
damages which may arise from the use, storage, or disposal of the
Materials.  To the extent permitted by
applicable law, ACT agrees to indemnify, defend, and hold harmless its
directors, officers, representatives, employees, and agent gains all losses,
expenses (including without limitation any legal expenses), claims, demands,
suits, or other actions arising from the use, storage, or disposal of the
Materials by the Recipient, except to the extent caused by the recklessness or
willful misconduct of ACT.

 

 

The parties hereby execute
this Agreement effective as the date last written below.

 

	
  INSTITUTION

  	
   

  	
   

  	
  RESEARCHER

  	
   

  
	
   

  	
  BC CANCER AGENCY

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Branko Palcic

  	
   

  	
  By:

  	
  /s/ Dr. Peter Lansdor

  	
   

  
	
  Name:

  	
  Branko Palcic, PhD

  	
  Name:

  	
  P. Lansdor

  
	
  Title:

  	
  Director, Technology Development

  	
  Title:

  	
  Senior Scientist

  
	
  Date:

  	
  February 16, 2000

  	
  Date:

  	
  Feb 15, 2000

  
	
   

  	
   

  
	
   

  	
   

  
	
  ADVANCED CELL TECHNOLOGY

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Jose B. Cibelli 

  	
   

  	
   

  
	
  Name:

  	
  Jose B. Cibelli, Ph.D.

  	
   

  
	
  Title:

  	
  Vice President of Research

  	
   

  
	
  Date:Exhibit 10.63

 

 

MATERIALS
TRANSFER AGREEMENT

 

This
Agreement is among Advanced Cell Technology, Inc. (“ACT”), IPK (“The
Institution”) and ANNA WOBUS IPK (“Researcher”). The Institution and the
Researcher are collectively referred to in this Agreement as the “Recipients.”

 

The parties hereby agree as follows:

 

1.             Requested Materials. The term “Materials” shall mean the
following tangible materials that are requested by Researcher and furnished by
ACT under the terms of this Agreement:

 

DNA               9-19         CMV-gfp

DNA               9-52         NSE-gfp

DNA               9-57         TM-gfp

 

“Materials”
shall also include any other materials routinely produced through use of such
tangible materials, including, for example, any progeny derived from a cell
line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated
from isolated DNA or RNA, recombinant proteins produced by a recombinant cell
line, recombinant proteins produced through use of isolated DNA or RNA, and
substances routinely purified from any source material included in the
materials (such as recombinant proteins isolated from a cell extract or supernatant by
non-proprietary affinity purification methods).

 

2.             Limited Use of Materials. The Recipients agree to use the Materials
only for the following experimental research under the direct supervision of
Researcher, and not for any other purpose:

 

Transfection of cells, selection of neo-resistant
clones, and differentiation in to dopaminergic neurons, and gene expression.

 

The
Recipients shall use the Materials only in compliance with all applicable
federal, state and local laws and regulations. The Recipients shall not use the
Materials in any in vivo experiments on human subjects without the prior
written consent of ACT

 

 

3.               Limited Disposition of Materials.   The
Materials shall remain on the premises of the Institution.  The Recipient shall not distribute any
Materials to any third party other than employees or students of Institution
who are working under the supervision of Researcher. Upon completion of the
research, or sooner at the request of ACT, the Recipient shall at the instruction
of ACT either destroy or return any unused Materials.

 

4.               Ownership of Materials.    The
Recipient acknowledges and agrees that all title and intellectual property
rights in the Materials are and shall be owned by ACT. The Recipient agrees to
execute and deliver and documents of assignment or conveyance to effectuate the
ownership rights of ACT in the Materials.

 

5.               Ownership of Intellectual
Property.   The
Researcher shall promptly inform ACT they intend to commercialize, to file a
patent application claiming, or to assert any intellectual property rights in
any research results obtained using the Materials. ACT agrees to negotiate in
good faith their respective ownership of the research results and any
intellectual property rights therein based on their relative contributions to
such rights and on any applicable laws relating to ownership of such rights,
including without limitation those relating to inventorship and authorship.

 

6.               License Option to ACT.   
Recipients shall notify ACT promptly of any discoveries, inventions,
data, modifications, new substances, and other results of any research using
the Materials (“Research Results”).  To
the extent permitted by law and any conflicting obligations to non-profit
sponsors of research, the Recipient hereby grants ACT a first option to obtain
an exclusive, worldwide license under any intellectual property rights in any Research
Results (the “License Option”).  ACT may
exercise the License Option upon written notice and the Recipient within thirty
(30) days from the date upon which ACT receives notice of the relevant Research
Results. In the event that ACT elects to exercise the License Option, the
parties shall attempt to negotiate in good faith to license agreement containing
commercially reasonable terms and pricing. 
If the parties are unable to reach agreement within ninety (90) days
after the date upon which ACT exercised the license option (the “Negotiation
Period”).  Then the Recipient will be
free to offer such rights to third parties; provided, however, that for a
period of one (1) year after the Negotiation Period 

 

2

 

the
Recipient may only offer such rights to third parties on terms and pricing which
in the aggregate are no more favorable than those last offered to ACT, unless
the more favorable terms and pricing have first been offered in writing to ACT
and either (i) ACT has declined in writing to accept such terms and pricing or
(ii) ACT has not responded after a period of thirty (30) days from the date of
such offer. The Recipient shall not use the Materials in research that is
subject to a licensing obligation to another commercial entity without the
prior written consent of ACT.

 

7.               Publication Rights.   Researcher
shall have the unrestricted right to publish the results of any research using
the Materials; however, in order to prevent the inadvertent loss of patent rights,
the Recipients shall provide ACT with pre-prints or abstracts of any proposed presentation
or paper describing any Research Results at least sixty (60) days prior to publication.

 

8.               No Warranties.   Any Materials delivered pursuant to this
Agreement are understood to be experimental in nature and may have hazardous properties.
ACT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND. EITHER EXPRESS
OR IMPLIED. WITH RESPECT TO THE MATERIALS, AND SPECIFICALLY DISCLAIMS ANY IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE
USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS
OF A THIRD PARTY.

 

9.               Indemnification. The Recipient assumes all liability for
damages which may arise from the use, storage, or disposal of the Materials.  To the extent permitted by applicable law, ACT
agrees to indemnify, defend, and hold harmless its directors, officers,
representatives, employees, and agent gains all losses, expenses (including
without limitation any legal expenses), claims, demands, suits, or other
actions arising from the use, storage, or disposal of the Materials by the
Recipient, except to the extent caused by the recklessness or willful misconduct
of ACT.

 

3

 

The parties hereby execute
this Agreement effective as the date last written below.

 

	
  INSTITUTION

  	
  RESEARCHER

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
   

  	
   

  	
  By:  

  	
   

  	
   

  
	
  Name:

  	
  Name:

  
	
  Title: 

  	
  Title: 

  
	
  Date:

  	
  Date:

  
	
   

  	
   

  
	
   

  	
   

  
	
  ADVANCED CELL TECHNOLOGY

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
  /s/ Jose B. Cibelli

  	
   

  	
   

  
	
  Name:

  	
  Jose B. Cibelli, Ph.D.

  	
   

  
	
  Title: 

  	
  Vice President of Research

  	
   

  
	
  Date:  JAN - 19
  - 2000

  	
   

  
								

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]